Search

Your search keyword '"Elinav, H."' showing total 119 results

Search Constraints

Start Over You searched for: Author "Elinav, H." Remove constraint Author: "Elinav, H."
119 results on '"Elinav, H."'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

3. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

6. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

7. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

8. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

9. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

11. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

12. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

14. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

15. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

16. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

17. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

20. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

21. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

24. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

25. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

26. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

28. Liver-related death among HIV/hepatitis C virus-co-infected individuals

29. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel

31. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

32. Infection-related and -unrelated malignancies, HIV and the aging population

33. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

34. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

35. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel.

37. Plantar Ulcers and Eyebrow-Hair Paucity

39. In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment.

41. Comparative evaluation of Sensititre YeastOne and CLSI M38-Ed3 reference method for determining echinocandin minimum effective concentrations against Aspergillus isolates.

42. Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome Parameters.

43. The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.

44. Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in Israel.

46. Two pandemics intertwined around one patient: Interstitial pneumonia as the first presentation of HIV/AIDS, be it Pneumocystis jirovecii , cytomegalovirus, SARS-CoV2 or all?-A case report.

47. The Relationship between Body Mass Index and In-Hospital Mortality in Bacteremic Sepsis.

48. Enterococci in Diabetic Foot Infections: Prevalence, Clinical Characteristics, and Outcomes.

49. Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study.

50. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA.

Catalog

Books, media, physical & digital resources